Barriers to gBRCA Testing in High-Risk HER2-Negative Early Breast Cancer

Despite the OlympiA trial demonstrating that early-stage, high-risk, HER2- germline BRCA1 and BRCA2 mutation (gBRCAm) positive breast cancer patients can benefit from PARPi in the adjuvant setting, the gBRCA testing rate in early-stage HR+/HER2− patients remains suboptimal compared to that in early-...

Descripción completa

Detalles Bibliográficos
Autores principales: Foroughi, Olivia, Madraswala, Shaheen, Hayes, Jennifer, Glover, Kara, Lee, Liam, Chaki, Moumita, Redpath, Stella, Yu, Agnes Weixuan, Chiu, David, Amanti, Kristen Garner, Gustavsen, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455724/
https://www.ncbi.nlm.nih.gov/pubmed/37623478
http://dx.doi.org/10.3390/jpm13081228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455724/
https://www.ncbi.nlm.nih.gov/pubmed/37623478
http://dx.doi.org/10.3390/jpm13081228

Ejemplares similares